department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Voydeya · pharmadog

pharmadog
drugs
Voydeya

drug

patient view →

danicopan

Marketedupdated 2mo ago

by Alexion Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Voydeya

generic

danicopan

indication

Paroxysmal Nocturnal Hemoglobinuria

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 29, 2029

~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Aug 2, 2038method-of-use (U-3933)US 12076319
Aug 2, 2038method-of-use (U-3933)US 12076319
Feb 25, 2035compositionUS 9796741
Feb 25, 2035compositionUS 9796741

FDA exclusivities (4)

Mar 29, 2031ODE-476Orphan Drug (7y)4.7y
Mar 29, 2031ODE-476Orphan Drug (7y)4.7y
Mar 29, 2029NCENew Chemical Entity (5y)2.7y
Mar 29, 2029NCENew Chemical Entity (5y)2.7y

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying danicopan

phase3A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHactive not recruitingn=80
—Danicopan Early Access Programavailable
—Long-term Safety of Danicopan: IPIG Registry-based Cohort Studyactive not recruitingn=50
—Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Dataactive not recruitingn=50
phase3Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysisrecruitingn=6
phase2A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degenerationterminatedn=365
phase3Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)completedn=86
phase2Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumabcompletedn=12

more trials →